Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + bevacizumab + PD-1 inhibitor followed by chidamide in first-line advanced hepatocellular carcinoma
ChiCTR2600126260Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and tucidinostat in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-Free Survival (PFS). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
bevacizumabtucidinostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600126260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126260.